A 46% overall response rate in a notoriously difficult-to-treat population is the number driving PMV Pharmaceuticals’ boldest regulatory bet yet. Among 76 evaluable patients with platinum-resistant or refractory ovarian cancer harboring a TP53 Y220C mutation, rezatapopt produced 35 responders, including four confirmed complete responses, assessed by RECIST 1.1 criteria. That efficacy profile is now the engine behind an NDA the company is preparing to submit, and the FDA’s decision on whether to accept that application for review is consequential enough that PMV has written it directly into the financial mechanics of an ongoing warrant offering.
The SEC filing is a 424B5 prospectus supplement tied to a common stock warrant raise, and buried in the pricing terms is a structural tell: the exercise price of the warrants drops to the greater of 33% of the initial exercise price or a defined floor, automatically, on the date PMV publicly announces FDA acceptance of the rezatapopt NDA. That is not routine warrant language. It is a built-in dilution event contingent on a single regulatory milestone, which means the company is essentially pricing investor risk around whether FDA accepts the filing at all. Acceptance is not approval, but it is the gate that confirms the agency finds the package sufficiently complete to begin a substantive review.
The clinical context matters here. Platinum-resistant ovarian cancer is a setting where options remain limited and heavily mutation-specific. Mirvetuximab soravtansine (Elahere) received full FDA approval in March 2024 for patients with FRα-positive disease, demonstrating that the agency will move on biomarker-selected populations with compelling single-arm data. Rezatapopt targets a completely different molecular subset, TP53 Y220C, a mutation that destabilizes the p53 protein’s folding rather than simply disabling its transcriptional function. PMV’s drug works by stabilizing the mutant conformation, a mechanism with no close approved analogue. Rezatapopt already carries Fast Track designation for this indication, which accelerates agency interactions but does not guarantee a favorable review clock.
The one number worth tracking now is the NDA acceptance date itself. A Refuse to File letter would collapse the warrant price trigger, freeze the program’s momentum, and force PMV to refile, likely costing six months or more. Acceptance, by contrast, flips the dilution mechanism live and signals that the 46% ORR dataset, whatever its limitations in a single-arm design, passed FDA’s threshold for substantive engagement. That decision, expected within 60 days of submission, is the closest thing this program has to a binary event before any advisory committee or approval action.
Source link: https://www.sec.gov/Archives/edgar/data/1699382/000119312526378780/d95425d424b5.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
